Status:
COMPLETED
Immune Biomarkers of Outcome From COVID-19
Lead Sponsor:
University Hospital Plymouth NHS Trust
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
A new virus to humans, first identified in December 2019, is causing a global pandemic with over 1 million infections and many thousands of deaths. The virus, SARS-CoV2, leads to coronavirus disease 2...
Eligibility Criteria
Inclusion
- Patients attending UHP with COVID-19 infection
- Participants capable of giving informed consent, or if not capable, assent from a personal or nominated consultee
- Age of 18 or over
- Confirmed COVID-19 infection by PCR or antibody testing
Exclusion
- Participants on immune suppressing medications within preceding 4 weeks (including systemic corticosteroids with average daily dose equivalent to prednisolone 20 mg)
- Participants on treatment with systemic chemotherapy
- Participants with known immunodeficiency states
- Participants already administered immunomodulating or antiviral agents as part of an interventional trial (this does not include non-specific therapies such as hydroxycholoroquine)
Key Trial Info
Start Date :
April 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 14 2021
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04436484
Start Date
April 29 2020
End Date
June 14 2021
Last Update
October 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Plymouth NHS Trust
Plymouth, Devon, United Kingdom, PL6 8DH